Feds file additional charges against ex-pharma CEO Martin Shkreli

The 33-year-old multi-millionaire millennial, who showed what kind of a pharmaceutical CEO – and human being – he is by raising the price of the life-saving drug Daraprim from $13.50 per pill to $750, shoved his hands in the pockets of his pants as he pleaded not guilty Monday to a superseding indictment in Brooklyn Federal Court.

He pleaded guilty to seven other criminal charges, including securities fraud, in December.

The case is U.S. v. Shkreli, 1:15-cr-637, U.S. District Court, Eastern District of New York (Brooklyn).

In the expanded indictment, Shkreli is accused of taking control of shares he wasn’t permitted to own, parking them with associates, and using them to help pay debts. Retrophin’s board ousted Shkreli in 2014, and later sued him for $65 million in connection with his alleged plundering of the company.

Shkreli stepped down from Turing Pharmaceuticals LLC and was sacked from KaloBios Pharmaceuticals Inc. after he and his lawyer Greebel were first arrested previous year.

While Shkreli’s lawyer, Ben Brafman, argued the indictment “adds nothing of value to the government’s case that still relies on a flawed theory”, the defendant faces eight counts of conspiracy and securities fraud during his time in MSMB Capital Management and Retrophin, and is free under a $5 million bail.

The judge told all the parties to return on July 14 and be prepared to set a schedule the trial and various motions. The price of Daraprim jumped from $13.50 per pill to $750 per pill.